172 related articles for article (PubMed ID: 32569019)
1. Prevalence and Characteristics of Postpartum Vulvovaginal Atrophy and Lack of Association With Postpartum Dyspareunia.
Lev-Sagie A; Amsalem H; Gutman Y; Esh-Broder E; Daum H
J Low Genit Tract Dis; 2020 Oct; 24(4):411-416. PubMed ID: 32569019
[TBL] [Abstract][Full Text] [Related]
2. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
3. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
Nappi RE; Seracchioli R; Salvatore S; Cagnacci A; Di Paolantonio T; Busacca M;
Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
[TBL] [Abstract][Full Text] [Related]
4. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of and risk factors associated with sexual health issues in primiparous women at 6 and 12 months postpartum; a longitudinal prospective cohort study (the MAMMI study).
O'Malley D; Higgins A; Begley C; Daly D; Smith V
BMC Pregnancy Childbirth; 2018 May; 18(1):196. PubMed ID: 29855357
[TBL] [Abstract][Full Text] [Related]
6. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of depression and anxiety in women newly diagnosed with vulvovaginal atrophy and dyspareunia.
Moyneur E; Dea K; Derogatis LR; Vekeman F; Dury AY; Labrie F
Menopause; 2020 Feb; 27(2):134-142. PubMed ID: 31688416
[TBL] [Abstract][Full Text] [Related]
9. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause.
Palacios S; Nappi RE; Bruyniks N; Particco M; Panay N;
Climacteric; 2018 Jun; 21(3):286-291. PubMed ID: 29553288
[TBL] [Abstract][Full Text] [Related]
10. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
11. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
12. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
[TBL] [Abstract][Full Text] [Related]
13. Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use.
Pingarron C; de Lafuente P; Ierullo AM; Poyo Torcal S; Maroto Díaz CJ; Palacios S
Gynecol Endocrinol; 2021 Jun; 37(6):562-566. PubMed ID: 33300371
[TBL] [Abstract][Full Text] [Related]
14. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
[TBL] [Abstract][Full Text] [Related]
15. [Sulphurous vaginal douching and vulvovaginal atrophy].
Costantino M; Conti V; Marongiu MB; Napolano G; Filippelli A
Clin Ter; 2017; 168(5):e300-e306. PubMed ID: 29044352
[TBL] [Abstract][Full Text] [Related]
16. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study.
Salvatore S; Nappi RE; Zerbinati N; Calligaro A; Ferrero S; Origoni M; Candiani M; Leone Roberti Maggiore U
Climacteric; 2014 Aug; 17(4):363-9. PubMed ID: 24605832
[TBL] [Abstract][Full Text] [Related]
17. The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy.
Salvatore S; Athanasiou S; Candiani M
Curr Opin Obstet Gynecol; 2015 Dec; 27(6):504-8. PubMed ID: 26536212
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of vulvar and vaginal symptoms during pregnancy and the puerperium.
Kennedy CM; Turcea AM; Bradley CS
Int J Gynaecol Obstet; 2009 Jun; 105(3):236-9. PubMed ID: 19275950
[TBL] [Abstract][Full Text] [Related]
19. Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study.
Palma F; Volpe A; Villa P; Cagnacci A;
Maturitas; 2016 Jan; 83():40-4. PubMed ID: 26421474
[TBL] [Abstract][Full Text] [Related]
20. Treatment to External Labia and Vaginal Canal With CO2 Laser for Symptoms of Vulvovaginal Atrophy in Postmenopausal Women.
Samuels JB; Garcia MA
Aesthet Surg J; 2019 Jan; 39(1):83-93. PubMed ID: 29726916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
